京东健康CEO曹冬表示，广药集团是京东健康最重要的战略伙伴之一，希望未来能够更好地将广药的优 质产品与京东健康的数字能力、服务场景紧密结合，挖掘新的增长机会，共同为更多用户提供优质的健 康服务。 据悉，自2017年开启深度合作以来，广药集团与京东健康始终秉持互信共赢的理念，合作成果丰硕，过 去三年双方合作业务更是保持了20%以上的高复合增长，为此次战略升级奠定了坚实基础。 就合作项目的落地，广药集团党委副书记、副董事长、总经理陈杰辉表示，接下来双方构建常态化全层 级协同机制，决策层引领、执行层推进、业务层联动；深化优势互补，聚焦大品种拓展等领域突破；拓 展创新边界，共探出海等新场景合作，力争今年合作业务大幅增长，明年向更高目标迈进。 本报讯(记者王镜茹)10月21日，广州医药集团有限公司(以下简称"广药集团")与京东健康在广州签署战 略合作协议。 根据合作协议，双方将以数智创新为核心引擎，整合产品、渠道、技术和服务资源，围绕供应链协同、 市场运营、用户服务等维度，构建多层次、一体化的合作体系，推动资源高效整合与价值释放，为消费 者提供更高效、便捷的健康产品与服务体验。 广药集团党委书记、董事长李小军表示，此次 ...

Core Viewpoint - The announcement indicates that Guangzhou Wanglaoji Pharmaceutical Co., Ltd., a subsidiary of Baiyunshan, has officially launched a Phase III clinical trial for the treatment of acute pharyngitis with the product "Keganli Yan Koufuye" [2] Group 1 - The Phase III clinical trial aims to evaluate the efficacy and safety of Keganli Yan Koufuye in treating acute pharyngitis, specifically for the external wind-heat syndrome [2] - The initiation of this clinical trial marks a significant step in the development of the product, potentially leading to its market introduction [2]

Core Viewpoint - Baiyunshan announced the initiation of a Phase III clinical trial for its product, Keguan Liyan Oral Solution, aimed at treating acute pharyngitis [1] Group 1: Company Information - Baiyunshan's subsidiary, Guangzhou Wanglaoji Pharmaceutical Co., Ltd., held a launch meeting for the Phase III clinical trial of Keguan Liyan Oral Solution [1] - Keguan Liyan Oral Solution received its new drug certificate and production approval in 1997, indicating its long-standing presence in the market [1] - The product is designed to relieve symptoms associated with wind-heat invasion and is primarily used for colds with external wind-heat and internal heat disturbance [1] Group 2: Clinical Trial Details - The Phase III clinical trial was approved by the National Medical Products Administration in February 2024, allowing for confirmatory clinical trials for acute pharyngitis [1] - The trial aims to validate the efficacy of Keguan Liyan Oral Solution in treating acute pharyngitis, which is categorized under the wind-heat syndrome [1]

Core Viewpoint - The company has officially launched a Phase III clinical trial for its proprietary product, Keguan Liyan Oral Solution, aimed at treating acute pharyngitis caused by external wind-heat syndrome [1] Group 1: Product Information - Keguan Liyan Oral Solution received its new drug certificate and production approval in 1997, making it a unique product of Wanglaoji Pharmaceutical [1] - The product is included in the 2025 edition of the Pharmacopoeia of the People's Republic of China and is known for its effects of dispelling wind, clearing heat, and detoxifying, primarily used for colds associated with external wind-heat invasion [1] Group 2: Clinical Trial Details - Wanglaoji Pharmaceutical obtained the clinical trial approval notice from the National Medical Products Administration in February 2024, allowing the company to conduct confirmatory clinical trials for acute pharyngitis [1] - The Phase III clinical trial has recently been officially initiated by Wanglaoji Pharmaceutical [1]

Core Viewpoint - The company announced the initiation of a Phase III clinical trial for its product, Keguanli Yan Oral Liquid, aimed at treating acute pharyngitis associated with external wind-heat syndrome [1] Group 1 - The clinical trial was organized by the company's subsidiary, Guangzhou Wanglaoji Pharmaceutical Co., Ltd. [1] - The trial is a significant step in the development of the company's product portfolio in the pharmaceutical sector [1]

Core Viewpoint - The company announced the initiation of a Phase III clinical trial for its proprietary product, Keguanli Yan Oral Liquid, aimed at treating acute pharyngitis caused by external wind-heat syndrome [1] Group 1: Product Information - Keguanli Yan Oral Liquid received its new drug certificate and production approval in 1997, making it a unique product of Wanglaoji Pharmaceutical [1] - The product is included in the 2025 edition of the Pharmacopoeia of the People's Republic of China and is known for its effects of dispelling wind, clearing heat, and detoxifying, primarily used for cold symptoms associated with wind-heat invasion [1] Group 2: Clinical Trial Details - Wanglaoji Pharmaceutical obtained the clinical trial approval notice from the National Medical Products Administration in February 2024, allowing the company to conduct confirmatory clinical trials for acute pharyngitis [1] - The Phase III clinical trial has recently been officially launched by Wanglaoji Pharmaceutical [1]

关于子公司药物进入 III 期临床试验的公告 证券代码：600332 证券简称：白云山 公告编号：2025－076 广州白云山医药集团股份有限公司 王老吉药业2024年克感利咽口服液的销售额为人民币1,828.52万元，除王老吉药 业生产的克感利咽口服液外，中国境内上市的克感利咽颗粒的生产厂家有葵花药业集 1 团（襄阳）隆中有限公司、临江市宏大药业有限公司等。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"公司"）子公司广州王老吉药业股份有限 公司（"王老吉药业"）于近日召开克感利咽口服液治疗急性咽炎（外感风热证）的 III期临床试验启动会，该III期临床试验项目正式启动。现将相关情况公告如下： 一、克感利咽口服液的基本情况 药物名称：克感利咽口服液 剂型：合剂 规格：10 mL/支 注册分类：2.3类新药 二、克感利咽口服液的其他情况 克感利咽口服液于1997年获得新药证书和生产批件，是王老吉药业独家品种，收 载于《中华人民共和国药典》2025年版一部，具有疏风清热，解毒利咽作用，主要用 ...

海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於子公司藥物進入III期臨床試驗的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年10月17日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 剂型：合剂 证券代码：600332 证券简称：白云山 公告编号：2025－076 广州白云山医药集团股份有限公司 关于子公司药物进入 III 期临床试验的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州白 ...

Core Viewpoint - Guangzhou Pharmaceutical Holdings Limited's subsidiary, Wanglaoji Pharmaceutical, has officially launched a Phase III clinical trial for its product, Keguanli Throat Oral Solution, aimed at treating acute pharyngitis [1] Group 1: Clinical Trial Details - The Phase III clinical trial for Keguanli Throat Oral Solution was initiated recently [1] - The product received its new drug certificate and production approval in 1997 and is listed in the 2025 edition of the Pharmacopoeia of the People's Republic of China [1] - The solution is indicated for symptoms related to wind-heat invasion and internal heat disturbance, primarily used for colds [1] Group 2: Regulatory Approvals - Wanglaoji Pharmaceutical obtained the clinical trial approval notice from the National Medical Products Administration in February 2024 [1] - The approval allows the company to conduct confirmatory clinical trials for acute pharyngitis [1]

Core Viewpoint - The announcement indicates that Guangzhou Wanglaoji Pharmaceutical Co., Ltd., a subsidiary of Baiyunshan, has officially launched the Phase III clinical trial for the drug Kegang Liyan Oral Liquid, aimed at treating acute pharyngitis [1] Group 1: Product Details - Kegang Liyan Oral Liquid is classified as a Class 2.3 new drug, with a specification of 10 mL per bottle, designed to dispel wind, clear heat, and detoxify [1] - The projected sales revenue for Kegang Liyan Oral Liquid in 2024 is estimated at RMB 18.2852 million [1] Group 2: Financial Investment - As of September 2025, the project has incurred research and development expenses of approximately RMB 18.1542 million (unaudited) [1]